Clinical Programs
The ONSEMBLE phase 2 open-label randomized trial for the second line treatment of patients with KRAS/NRAS mutated metastatic colorectal cancer (MCRC) is designed to
- Demonstrate onvansertib’s contribution to SoC
- Confirm optimal dosing
- Demonstrate onvansertib’s contribution to SoC
- Operate with capital efficiency
Enrollment Criteria
ENDPOINTS
Primary
- Objective Response Rate: CR + PR
Key Secondary
- Progression-Free Survival
Other Secondary
- Disease Control Rate: CR + PR + SD
- Duration of Response: DoR
- Overall Survival: OS
- Reduced MAF association with ORR, PFS, DCR, DoR, OS